Group 1 - New Yuan Technology (300472) has received an administrative penalty notice, indicating that the company is involved in false statement violations, which are now clearly defined [1] - From May 2022 to June 2024, New Yuan Technology falsely recognized operating income, operating costs, and profits by fabricating distributed storage equipment integration business [1] - Investors who purchased New Yuan Technology stock between April 26, 2023, and March 28, 2025, and sold or continued to hold the stock after March 28, 2025, are eligible to initiate claims for damages [1] Group 2 - Tai'an Tang (002433) has received an administrative penalty decision from the Guangdong Regulatory Bureau of the CSRC, confirming that the company had false records in its annual reports from 2018 to 2021 [2] - Tai'an Tang failed to disclose related party transactions as required, resulting in significant omissions in its annual reports from 2018 to 2021 and the semi-annual report of 2022 [3] - Investors who bought Tai'an Tang stock between November 23, 2018, and May 4, 2023, and sold or held the stock after May 4, 2023, can also initiate claims for damages based on previous successful investor lawsuits [3]

Core Viewpoint - The article discusses the issue of major shareholders occupying funds from listed companies, which harms the interests of the companies and minority shareholders, and highlights the efforts of regulatory bodies and the China Securities Investor Service Center in addressing this problem through legal actions and shareholder rights protection [1][2][3]. Group 1: Regulatory Actions - The China Securities Regulatory Commission (CSRC) and stock exchanges have taken strict measures to combat the malicious occupation of funds, emphasizing that occupied funds must be repaid, with deadlines for rectification and no exemption from delisting [1][2]. - The CSRC has been enhancing policies to address fund occupation, including clear deadlines for rectification and increased penalties for major offenders [2][3]. Group 2: Shareholder Rights Protection - Shareholders are encouraged to actively exercise their rights and pursue legal actions against major shareholders who occupy company funds, with the China Securities Investor Service Center playing a crucial role in this process [3][4]. - The legal framework provided by company law and securities law allows affected shareholders to initiate derivative lawsuits to recover occupied funds [3][4]. Group 3: Successful Cases - The China Securities Investor Service Center has successfully initiated derivative lawsuits, leading to significant recoveries from responsible parties, including the notable *ST Modern case, which set a precedent for shareholder rights protection [4][5]. - In the *ST Modern case, the court ruled that the controlling shareholder must repay approximately 240 million yuan, with responsible executives also bearing joint liability [5]. Group 4: Ongoing Efforts and Challenges - The China Securities Investor Service Center continues to expand its efforts in shareholder rights protection, collaborating with regulatory bodies to ensure the recovery of occupied funds [6][7]. - Despite progress, challenges remain, such as high litigation costs that hinder the ability of investor protection agencies to pursue derivative lawsuits effectively [8][9]. - There is a call for improved institutional support, including the possibility of waiving litigation fees for investor protection agencies when filing derivative lawsuits [8][9]. Group 5: Future Directions - The China Securities Investor Service Center aims to enhance its role in protecting shareholder rights and promoting corporate governance through legal actions against fund occupation [10]. - There is a suggestion for centralized jurisdiction for derivative lawsuits to improve judicial consistency and efficiency in handling complex cases related to fund occupation [9][10].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has released its annual top ten investor protection cases, highlighting various legal actions and mechanisms aimed at safeguarding investor rights in the capital market [1][2]. Group 1: Investor Protection Cases - The top ten cases include significant legal actions such as representative lawsuits and mediation of securities fraud, market manipulation, and private fund disputes [1]. - Notable cases include the first-ever representative lawsuits for market manipulation and the first case of public nomination of independent directors by an investor protection agency [1][9]. Group 2: Specific Cases - The representative lawsuits for Jin Tong Ling and Mei Shang Ecological involve collective actions against financial fraud, with both companies accused of inflating profits and failing to disclose related party transactions [2][3]. - The Jin Tong Ling case involves approximately 50,000 investors, while the Mei Shang Ecological case involves over 33,000 investors [3]. Group 3: Regulatory Actions - The CSRC has taken strict actions against fraudulent issuance and market manipulation, with a notable case involving Evergrande Group, which faced a fine of 4.175 billion yuan for fraudulent bond issuance [4][5]. - The case against Wang, who manipulated the market using 145 accounts, resulted in a civil lawsuit with a total penalty of 5.7 billion yuan [5][6]. Group 4: Innovative Mediation Mechanisms - The "Tai An Tui" case marked the first successful zero-cost representative lawsuit through judicial collaboration, recovering 572 million yuan for investors [7]. - The introduction of a "demonstration mediation + arbitration confirmation" mechanism has successfully resolved private fund disputes, with 97 investors receiving nearly 300 million yuan in compensation [8][9]. Group 5: Independent Director Nomination - The first public nomination of an independent director by an investor protection agency occurred in the case of First Medical, which is seen as a significant step towards improving the independent director selection mechanism [9].

Core Viewpoint - The new delisting regulations in A-shares are intensifying, leading to an accelerated "survival of the fittest" process in the market, with a recent surge in delisting risk warnings from multiple companies [1] Group 1: Companies at Risk - ST Xintong is facing delisting risk due to 368 million yuan in non-operating fund occupation, with a two-month deadline for rectification [2] - ST Ningke is projected to incur a loss of 580 to 650 million yuan in 2024, with non-deductible revenue below 300 million yuan, risking delisting if the annual report receives an "unable to express opinion" audit [5][6] - ST Dayao has seen its market value drop below 500 million yuan, making it the first trading delisting stock of 2025, with a stock price plummeting to 1.18 yuan [7][8] - ST Modern has not completed regulatory rectification on time and risks delisting if it fails to submit an audit proof within two months [9][10] Group 2: Regulatory Background - The 2025 delisting regulations have tightened financial indicators, including continuous losses, revenue below 300 million yuan with negative net assets, and excessively low market value [11] - Regulatory scrutiny on information disclosure violations and financial fraud has intensified, exemplified by the case of Dongfang Group, which inflated revenue by 16.1 billion yuan over four years [11] Group 3: Investor Guidance - Investors are advised to avoid high-risk stocks, particularly ST and *ST stocks, companies with continuous losses, and those with abnormal stock price fluctuations [12] - Caution is advised against "doomsday speculation," as some ST stocks may experience short-term surges followed by sharp declines due to major shareholders offloading [13] - Investors should focus on the quality of financial reports, particularly looking for non-standard audit opinions and issues related to major shareholder fund occupation [14] - A rational perspective on "shell protection" expectations is necessary, as the accelerated delisting process under new regulations poses high risks for speculative bottom-fishing [15]

柯少芳： 特此函告。 深 圳 证 券 交 易 所 经查，广东太安堂药业股份有限公司（以下简称太安退或者 公司）于 2023 年 9 月 15 日晚披露的《关于收到中国证券监督管 理委员会立案告知书的公告》显示，因涉嫌信息披露违法违规， 公司被中国证监会立案调查。2023 年 9 月 15 日至 19 日，因司 法强制执行，你所持太安退股份通过二级市场减持方式被处置， 减持数量 549.48 万股，减持比例 0.72%，减持金额 1,773.11 万 元。 你作为公司控股股东太安堂集团有限公司的一致行动人，在 太安退被立案调查期间减持公司股份，违反了本所《股票上市规 则（2023 年 8 月修订）》第 1.4 条、第 3.4.1 条、第 3.4.13 条 的规定，以及《上市公司股东及董事、监事、高级管理人员减持 股份实施细则》第九条的规定。 1 关于对柯少芳的监管函 公司部监管函〔2024〕第 140 号 深圳证券交易所 上市公司管理二部 2024 年 8 月 5 日 2 ...

股票代码：002433 股票简称：太安退 公告编号：2024-057 广东太安堂药业股份有限公司 广东太安堂药业股份股份有限公司（以下简称"公司"）于2024年6月5日收 到深圳证券交易所（以下简称"深交所"）下发的《关于广东太安堂药业股份有 限公司股票终止上市的决定》（深证上2024【435】号），深交所决定终止公司 股票上市。根据《深圳证券交易所股票上市规则》（以下简称《股票上市规则》）、 《关于退市公司进入退市板块挂牌转让的实施办法》等的相关规定，公司应当在 股票被终止上市后及时做好相关工作，以确保公司股份在摘牌后四十五个交易日 内可以进入全国中小企业股份转让系统有限责任公司依托原证券公司代办股份 转让系统设立并代为管理的两网公司及退市公司板块（以下简称"退市板块"） 挂牌转让。 关于公司股票终止上市暨摘牌的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.公司股票已被深圳证券交易所决定终止上市，公司股票进入退市整理期的 起始日为2024年6月14日，退市整理期为十五个交易日，最后交易日期为2024年7 月4日。 2.公司股票已被深圳 ...

公司股东深南信创科技（深圳）有限公司保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 2024年7月3日，广东太安堂药业股份有限公司（以下简称"公司"）收到持 股5%以上股东深南信创科技（深圳）有限公司（以下简称"深南信创"）发来的 《告知函》，深南信创司通过证券交易所集中竞价方式，截至发函时共累计持有 公司股份49,825,353股，占太安堂总股本6.50%，相较之前股份增加10,267,700 股，所占比例变动达1.34%。 现将权益变动情况公告如下： | 1.基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人 | | 深南信创科技（深圳）有限公司 | | | 住所 | | 广东省深圳市福田区福田街道福安社区益田路 大厦 4207 | 4068 号卓越时代广场 | | 权益变动时间 | | 2024 年 7 月 3 日 | | | 股票简称 | 太安退 | 股票代码 | 002433 | | 变动类型 （可多选） | 增加 |  减少□ 一致行动人 | 有□ 无 ...

股票代码：002433 股票简称：太安退 公告编号：2024-056 广东太安堂药业股份有限公司 关于公司股票进入退市整理期交易第八次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.公司股票于退市整理期届满的次一交易日摘牌，公司股票终止上市。 2.公司股票进入退市整理期的起始日为2024年6月14日，退市整理期为十五 个交易日，预计最后交易日期为2024年7月4日。 3.公司股票将在退市整理期交易十五个交易日，本公告日(2024年7月4日) 是第15个交易日，是最后一个交易日，交易期满将被终止上市，敬请投资者审慎 投资，注意风险。 一、公司股票在退市整理期间的的证券代码、证券简称及涨跌幅限制 1.证券简称:太安退 2.证券代码:002433 3.涨跌幅限制：股票进入退市整理期的首个交易日不实行价格涨跌幅限制， 此后每个交易日的涨跌幅限制为10%。 二、公司股票退市整理期交易起始日及交易期限 公司股票进入退市整理期的起始日为2024年6月14日，退市整理期为十五个 交易日，预计最后交易日为2024年7月4日。如证券交易日期出现调整, ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 股票代码：002433 股票简称：太安退 公告编号：2024-055 广东太安堂药业股份有限公司 关于公司股票进入退市整理期交易第七次风险提示公告 2.证券代码:002433 3.涨跌幅限制：股票进入退市整理期的首个交易日不实行价格涨跌幅限制， 此后每个交易日的涨跌幅限制为10%。 1.公司股票于退市整理期届满的次一交易日摘牌，公司股票终止上市。 2.公司股票进入退市整理期的起始日为2024年6月14日，退市整理期为十五 个交易日，预计最后交易日期为2024年7月4日。 3.公司股票将在退市整理期交易十五个交易日，本公告日(2024年7月3日) 是第14个交易日，剩余1个交易日，交易期满将被终止上市，敬请投资者审慎投 资，注意风险。 4.退市整理期间，公司将不筹划或实施重大资产重组事项。 5.请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通、深股通等业务。 6.对于将在股票摘牌后至完成退市板块初始登记期间到期的司法冻结业务， 建议有权机关在股票摘牌前通过原协 ...

股票代码：002433 股票简称：太安退 公告编号：2024-054 广东太安堂药业股份有限公司 关于公司股票进入退市整理期交易第六次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.公司股票于退市整理期届满的次一交易日摘牌，公司股票终止上市。 2.公司股票进入退市整理期的起始日为2024年6月14日，退市整理期为十五 个交易日，预计最后交易日期为2024年7月4日。 3.公司股票将在退市整理期交易十五个交易日，本公告日(2024年7月2日) 是第13个交易日，剩余2个交易日，交易期满将被终止上市，敬请投资者审慎投 资，注意风险。 4.退市整理期间，公司将不筹划或实施重大资产重组事项。 5.请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通、深股通等业务。 6.对于将在股票摘牌后至完成退市板块初始登记期间到期的司法冻结业务， 建议有权机关在股票摘牌前通过原协助执行渠道提前办理续冻手续。 广东太安堂药业股份股份有限公司（以下简称"公司"）于2024年6月5日收 到深圳证券交易所（以下简称"深交 ...